Ying-Qing Wang

1.0k total citations
29 papers, 774 citations indexed

About

Ying-Qing Wang is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Ying-Qing Wang has authored 29 papers receiving a total of 774 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Oncology. Recurrent topics in Ying-Qing Wang's work include Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (12 papers) and Multiple Myeloma Research and Treatments (6 papers). Ying-Qing Wang is often cited by papers focused on Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (12 papers) and Multiple Myeloma Research and Treatments (6 papers). Ying-Qing Wang collaborates with scholars based in China, Sweden and Italy. Ying-Qing Wang's co-authors include Ze‐Hong Miao, Jiangning Yang, Bertil B. Fredholm, Jingkang Shen, Xia‐Juan Huan, Jian Ding, Bing Xiong, Xin Wang, Danyan Cao and Yanlian Li and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Biochemical Pharmacology.

In The Last Decade

Ying-Qing Wang

28 papers receiving 766 citations

Peers

Ying-Qing Wang
Xueyang Jiang China
Lijun Zhu China
Qiang Qiu China
Seung Hun Jeong South Korea
Tony Eight Lin Taiwan
Shigeo Sasaki Japan
Lu Wen China
Ya-Ming Xu United States
Subhankar Biswas India
Xueyang Jiang China
Ying-Qing Wang
Citations per year, relative to Ying-Qing Wang Ying-Qing Wang (= 1×) peers Xueyang Jiang

Countries citing papers authored by Ying-Qing Wang

Since Specialization
Citations

This map shows the geographic impact of Ying-Qing Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying-Qing Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying-Qing Wang more than expected).

Fields of papers citing papers by Ying-Qing Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying-Qing Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying-Qing Wang. The network helps show where Ying-Qing Wang may publish in the future.

Co-authorship network of co-authors of Ying-Qing Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ying-Qing Wang. A scholar is included among the top collaborators of Ying-Qing Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying-Qing Wang. Ying-Qing Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhou, Yushan, Li Wang, Ruiyi Ren, et al.. (2025). Structure-Based Discovery of a Series of Novel MAT2a Inhibitors. ACS Medicinal Chemistry Letters. 16(4). 646–650. 1 indexed citations
3.
Zhang, Qian, Qian Wu, Xia‐Juan Huan, et al.. (2024). Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy. Biochemical Pharmacology. 223. 116198–116198. 4 indexed citations
4.
Su, Ailing, Changqing Tian, Xubin Bao, et al.. (2023). Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells. Life Sciences. 332. 122129–122129. 2 indexed citations
5.
Sun, Lin, Qian Wu, Xia‐Juan Huan, et al.. (2022). Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 20(12). 1785–1798. 1 indexed citations
6.
Wu, Qian, Yueyue Yang, Lin Sun, et al.. (2022). Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities. European Journal of Medicinal Chemistry. 239. 114519–114519. 7 indexed citations
7.
Wu, Qian, Dan-Qi Chen, Lin Sun, et al.. (2021). Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1. Biochemical Pharmacology. 185. 114435–114435. 11 indexed citations
8.
Yang, Bowen, Qian Wu, Xia‐Juan Huan, et al.. (2020). Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors. Bioorganic & Medicinal Chemistry Letters. 33. 127749–127749. 9 indexed citations
9.
Chen, Huadong, et al.. (2020). Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter. Cell Death and Disease. 11(1). 71–71. 11 indexed citations
10.
Tian, Changqing, Lin Chen, Huadong Chen, et al.. (2019). Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l-kynurenine. Cell Death and Disease. 10(8). 557–557. 21 indexed citations
11.
Hu, Jianping, Xia‐Juan Huan, Shanshan Song, et al.. (2019). A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. Investigational New Drugs. 38(3). 700–713. 7 indexed citations
12.
Hu, Jianping, Ying-Qing Wang, Yanlian Li, et al.. (2018). Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. European Journal of Medicinal Chemistry. 150. 156–175. 19 indexed citations
13.
14.
Hu, Jianping, Ying-Qing Wang, Yanlian Li, et al.. (2017). Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. European Journal of Medicinal Chemistry. 137. 176–195. 30 indexed citations
15.
Yi, Jun-Mei, Xia‐Juan Huan, Shanshan Song, et al.. (2016). Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44. Molecular Cancer Therapeutics. 15(7). 1495–1503. 32 indexed citations
16.
Fredholm, Bertil B., Jiangning Yang, & Ying-Qing Wang. (2016). Low, but not high, dose caffeine is a readily available probe for adenosine actions. Molecular Aspects of Medicine. 55. 20–25. 79 indexed citations
17.
18.
Wang, Wei, Ying-Qing Wang, Tao Meng, et al.. (2014). MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189. Molecular Cancer Therapeutics. 13(6). 1480–1491. 29 indexed citations
19.
Cao, Danyan, Tiantian Chen, Ying-Qing Wang, et al.. (2013). Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain. Journal of Medicinal Chemistry. 56(10). 3833–3851. 97 indexed citations
20.
Manzo, Stefano Giustino, Zhaoli Zhou, Ying-Qing Wang, et al.. (2012). Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II. Cancer Research. 72(20). 5363–5373. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xueyang Jiang Breakdown of academic impact, for papers by Lijun Zhu Breakdown of academic impact, for papers by Qiang Qiu Breakdown of academic impact, for papers by Seung Hun Jeong Breakdown of academic impact, for papers by Tony Eight Lin Breakdown of academic impact, for papers by Shigeo Sasaki Breakdown of academic impact, for papers by Lu Wen Breakdown of academic impact, for papers by Ya-Ming Xu Breakdown of academic impact, for papers by Subhankar Biswas
Rankless by CCL
2026